Skip to main content

' Efficacy and safety of co-administered cagrilintide and semaglutide(CagriSema 2.4 mg/2.4 mg) once-weekly versus semaglutide 2.4 mg,cagrilintide 2.4 mg and placebo in people with chronic kidneydisease and type 2 diabetes living with overweight or obesity.'

Open
  • Protocol code: NN9388-7700
  • EudraCT code: No aplica
  • Research group: Nephrology and kidney transplantation
  • Service: Nephrology
  • Principal investigator:  Soler Romeo, Maria Jose
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase II